The news that US regulators have rejected Kala Pharmaceuticals Inc.'s dry eye disease therapy is no great surprise but the company still believes that KPI-121 will be able to make its mark in a potentially lucrative and wide-open market.
Kala Needs Big STRIDE To Get Dry Eye Drug OK
The US FDA has issued a complete response letter for KPI-121 but Kala hopes to resubmit the drug during the first half of next year backed by data from the ongoing STRIDE 3 study.
